[Pharmacokinetic study of 4-(hydroxycarbophenyl) retinamide (RII) in cancer patients].
RII, a new analog of retinoic acid, is an effective anticarcinogenic drug. The pharmacokinetic characteristics of RII were studied by HPLC in thirteen cancer patients after oral administration. The sensitivity to detect RII was greater than 3 ng and CV values of duplicate samples were 1.88-6.62. The results showed that peak concentration of RII in plasma appeared at 8 hrs after oral administration of 200 mg of the drug, and the mean peak concentration in serum was 3.612 +/- 1.099 micrograms/ml. Half life time (T1/2) was 6.62 +/- 0.81 hrs. The area under the drug-time curve (AUC) was 35.70 +/- 14.46 micrograms hr/ml. The results indicate that it is advisable to take RII twice a day.
Gu
Q M
QM
Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing.
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D014212:Tretinoin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000378:metabolism*
D000970:Antineoplastic Agents; D014212:Tretinoin; C045860:N-(4-carboxyphenyl)retinamide